WVE — Wave Life Sciences, Inc.

WVE

SHORT CANDIDATEMeanRev

Composite

31.10

Technical

5.20

Fundamental

39.80

Rank

—

Price

3.45

Hurst

0.16

As of

Oct 28, 2026

Daily

Wave Life Sciences, Inc.

HealthcareBiotechnology

Wave Life Sciences is a clinical-stage biotechnology firm developing RNA-based therapeutic treatments using its proprietary PRISM platform, which integrates multiple RNA technology approaches with genetic research. The company's pipeline includes programs targeting obesity, alpha-1 antitrypsin deficiency, liver disease linked to PNPLA3 mutations, Duchenne muscular dystrophy, and Huntington's disease, along with earlier-stage research initiatives. Founded in 2012, the company is based in Cambridge, Massachusetts.

Market cap

$681.4M

P/E (trailing)

—

P/E (forward)

-2.98

PEG ratio

—

Dividend yield

0.00%

Beta

-1.43

52w range

3.04 – 21.73

Return on equity

-78.80%

Profit margin

-296.86%

Revenue growth

+73.00%

Earnings growth

—

Price history

1Y: 3.59 (-60.3%) · range 3.09–21.31

Cycle position

21/ 100 cycle scoreENTRY ZONE

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 54 · MODERATE · exit proximity 0

Conviction

42/ 100 · maturity 43%

VScore.2218

Buildup.2650

EMA entry setup.3254

Fundamentals.1940

Volume profile

POC

5.79

Price vs POC

-38.0%

Overhead supply

88%

Runway

+59.1%

Value area 4.27–6.57 · 88% of 120d volume overhead · heavy supply

Contributing sources

Source	Score	Last seen
earnings-surprise	0.706	Oct 30, 2026

Forward returns

Not yet labeled — the study prices these as positions mature.